This Cost Recovery Implementation Statement (CRIS) provides information on how the Therapeutic Goods Administration (TGA), within the Department of Health, implements and cost recovers its regulatory activities. The TGA's regulatory activities are associated with the registration and listing of medicines and inclusion of medical devices, including in vitro diagnostic (IVD) devices, and biologicals onto the Australian Register of Therapeutic Goods (ARTG) and the ongoing monitoring and surveillance of them.
Policy and statutory authority to cost recover
Cost recovery model
Design of cost recovery charges
Consultation on the 2022-23 fees and charges
Financial and non-financial performance
Key forward events
CRIS approval and change register
Appendix 1 - Financial performance by industry sector group
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.